We firstly investigate based on 2022 European Leukemia Net (ELN) risk stratification, whether standard-dose cytarabine based multiagent sequential chemotherapy (SDMSC) is more beneficial than high-dose cytarabine (HDAC) monotherapy in consolidation for the survival of adult acute myeloid leukemia (AML) patients.
One hundred and eighty-three AML patients with complete remission (CR) were evaluated.
The 3-year relapse rate was 33.4% in the HDAC group and 50.5% in the SDMSC group (